 Sudden death empiric amiodarone therapy symptomatic hypertrophic cardiomyopathy Amiodarone symptoms sudden death patients hypertrophic cardiomyopathy HC treatment weeks maintenance mg/day patients HC drug symptoms refractory conventional drug therapy calcium antagonists beta blockers Twenty-one patients ventricular tachycardia VT Holter monitoring Amiodarone patients New York Heart Association functional class status months exercise duration patients mean follow-up period years sudden deaths months initiation treatment survival rates survival rate patients VT patients VT years Sudden death abolition VT Holter monitoring Amiodarone ventricular peak rate radionuclide angiography patients Decrease peak ventricular filling rate days amiodarone therapy patients subsequent sudden death